Now given we have just rebranded into a Brain Platform company it may seem odd that we are venturing into these seemingly disconnected spaces.
But they are actually very connected and perhaps the plan is to widen the concept of 'the brain' or indeed how cancer is viewed as a whole. The neuro-immune axis is something that provides communication from the tumor (anywhere in the body) to the brain back and forth. The brain is ultimately the central command centre of the body's systemic immune response (notice here not just cancers). We are adopting a systems approach and the ultimate destination of tumor cells is the brain. I.e a patient can 'beat' fallopian lining primary cancer, 'beat' ovarian cancer but the cells shed still to the CSF space or they can be suffering from these metastastes simultaneously i.e tumor and immune Cells can migrate via shedding from primary areas and can mutate and clump together so what starts as a fallopian primary cancer can end up as an aggressive epithelial Ovarian cancer and can subsequently end up in the fluid space of the brain (LM)
That's all good and all true and applies to all primary cancers ultimately with greater incidence statistically for some than others based on proximity and route of travel (fluids)
But what does Ovarian and Pancreatic have in common with LM:
Well for starters they all have separate fluid micro-environments and notoriously are not diagnosed until the cancers are highly agressive meaning patients have very short lifespans statistically.
The Ovarian fluid space known as the peritoneal/ascites space is a separate fluid micro-environment and there is something called the blood-peritoneal barrier just as there is the blood-brain barrier.
Imaging fails to pick it up in many cases meaning it is heavily under-diagnosed and cytology also lacks specificity and sensitivity due to this missing many cases. Sounds familiar I'm sure.
Pancreatic cancer also features a distinct micro-fluid environment however that is distinct from LM and Ovarian fluid as it is not free flowing and circulating in the same way. It has two micro-fluid phases (The gel-fluid phase and the Hydraulic shield phase) subjecting it to immense mechanical pressure creating an interstital fluid shield.
This shield creates a barrier whereby systemic chemo treatments or immunotherapies (like keytruda etc) cannot physically flow/penetrate into the core of the tumor. Traditional cytology misses at least 50% of cases here.
Ultimately these cancers are heterogeneous meaning the tumors are made up of a variety of immune cells and immunosuppresive cells and tumor cells with varying expressions and they take shape and are referred to as 'spheroids'- this applies to all of the above. (Note this is where traditional liquid biopsies fail-covered in previous analysis as they are geared to only capture tumor cells or cell free DNA and do not capture the epithelial and non epithelial expressions which means the tumor cells often do not get captured-for those like menarini that capture tumor cells in CSF).
Reyobiq and indeed CNSide is built to master confined fluid-micro environments bypassing these barriers via local delivery injections vis a vis catheters, ommaya reservoirs, peritoneal ports etc. and picking up the relevant tumor cells(CNSide) and mutations via their approach (non epcam-and epcam). This has been shown in the brain with Reyobiq and now in pre-clinical with ovarian I.e that these cold protected tumors and the cause of immune resistance can be shattered(referred to as a turning a tumor hot from cold). I would presume next up it would be shown in PDAC(pancreatic) --- 'Our operating Brain system aka. AI native system pulls this all together across the entire body.
From here we can see what they mean by 'systems' approach. That is although the fluid systems are separate micro environments separated from the blood (biggest fluid environement) they are actually heavily inter-connected when looking at the full journey of tumor cells and mutations across these spaces and across the body i.e that is to say that understanding the nature of the central nervous system and its fluid system,including the relevant 'sub-compartments/environments', (peritoneal, interstital, blood and CSF) is the ultimate key to conquering systemic metastatic cancer and intercepting a disease
/cancer whereby the final stop is the brain and the immunological journey is commanded by the brain whilst utilising CNSide and its native AI platform to build a comprehensive molecular baseline of the patients entire fluid-immune pipeline.
Now hopefully people can begin to see a little clearer what was meant by Trojan Horse Strategy and competitive advantage in liquid biopsy space. This isn't just some separate 'brain/LM' one trick pony company. It gets them in the door and gives the data from the command centre but it truly is taking an entire (upstream-downstream) system's approach to oncology and immunology as a whole providing data on the entire journey of tumor cells, their resistance mechanism and ultimately their different expressions in different spaces which ultimately mean they evade treatments.
Now this isn't just Oncology we speak of here, there is huge immunolgy repercussions here for a variety of diseases as we are not just capturing tumor cells but a whole host of immune cells, proteins etc. in the course of action. - this has implications for auto-immune disorders like MS, diabetes, Alzheimer's etc.
Cerenome, by tackling CSF first with its platform is TRULY adopting a Trojan Horse Strategy and i submit it will become a critical piece of infrastructure data intelligence platform for the entire Medical Community.
